Michel Haddad

Mr. Michel Haddad

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Cleaner Production
Verified
Journal Article
Closed access
FFFranz Fuerst
Franz Fuerst
MHMichel Haddad
Michel Haddad
HAHassan Adan
Hassan Adan

5 November 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JMJair Mari
Jair Mari
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
DPDaniel Prates-Baldez
Daniel Prates-Baldez
MHMichel Haddad
Michel Haddad
Naielly Rodrigues da SilvaNaielly Rodrigues da Silva
Naielly Rodrigues da Silva
FKFlavio Kapczinski
Flavio Kapczinski
Objective This study aims to conduct an overview on the comparative efficacy of valproate in acute mania, bipolar depression and maintenance treatment of bipolar disorder (BD). Method We performed an overview of systematic reviews with meta-analyses of randomised controlled trials (RCTs), registered in PROSPERO (CRD42024497749). We searched Medline and Cochrane Database of Systematic Reviews. Summary measures comparing valproate with placebo or other active drugs were described. Results We included 26 systematic reviews. For acute mania (31 RCTs, n=4376), valproate showed a significantly better response than placebo in two high-quality systematic reviews (RR=1.42; 95% CI: 1.19 to 1.71) (OR=2.05; 95% CI: 1.32 to 3.20). No significant differences with lithium were found in most outcomes. Valproate had similar efficacy to quetiapine and lower efficacy compared with risperidone, with conflicting results when compared with olanzapine. In bipolar depression (7 RCTs, n=399), valproate was more effective than placebo in reducing depressive symptoms (OR=2.80; 95% CI: 1.26 to 6.18) and achieving remission (OR=2.4; 95% CI: 1.09 to 5.29) (OR=2.15; 95% CI: 0.82 to 5.6), considering the results of three high-quality systematic reviews. No significant difference was observed with lithium, lurasidone, quetiapine or olanzapine plus fluoxetine, but valproate showed superior efficacy to aripiprazole, ziprasidone and agomelatine. In maintenance treatment (11 RCTs, n=1063), valproate was superior to placebo in preventing relapse of any mood episode in two high-quality systematic reviews (RR=0.63; 95% CI: 0.48 to 0.83) (RR=0.63; 95% CI: 0.47 to 0.83). No significant difference was found with lithium, olanzapine or lamotrigine. Conclusion This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study.

12 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
MHMichel Haddad
Michel Haddad
TVThiago Viola
Thiago Viola
FSFranciele Franco Scarante
Franciele Franco Scarante
Naielly Rodrigues da SilvaNaielly Rodrigues da Silva
Naielly Rodrigues da Silva
JMJair Mari
Jair Mari
Background: Depression is one of the leading causes of disability worldwide. Among pharmacological treatments, fluvoxamine—an early SSRI with a distinct pharmacological profile—has been recently reappraised for its broader clinical relevance. Objective: To assess the efficacy of fluvoxamine in the treatment of depression compared to placebo and other antidepressants through a comprehensive overview of systematic reviews and meta-analyses. Methods: A systematic search was conducted in MEDLINE and the Cochrane Central Register of Controlled Trials, including systematic reviews and meta-analyses of randomized controlled trials evaluating fluvoxamine’s efficacy. Reviews were eligible if they included adults diagnosed with depressive disorders based on the DSM or ICD criteria. Reviews focusing on other psychiatric disorders, comorbidities, tolerability, or economic evaluations were excluded. Data extraction included effect size measures and methodological quality assessments using the AMSTAR-2 tool. Results were synthesized by comparing fluvoxamine to placebo, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants. Results: A total of 74 reviews were identified, of which 14 systematic reviews met the inclusion criteria after screening and full-text analysis. These reviews, published between 1994 and 2021, predominantly involved nine pairwise meta-analyses and five network meta-analyses, comparing fluvoxamine with placebo and various antidepressants. Fluvoxamine demonstrated consistent superiority over placebo in achieving treatment response and remission outcomes. Comparisons with imipramine, clomipramine, amitriptyline, dothiepin, paroxetine, fluoxetine, citalopram, mianserin, nortriptyline, and moclobemide generally revealed no significant differences in efficacy. However, some reviews indicated that venlafaxine and mirtazapine were superior to fluvoxamine in certain outcomes, while fluvoxamine demonstrated greater efficacy than desipramine in one review. Sertraline and milnacipran showed mixed or review-quality-dependent results, with one low-quality review favoring milnacipran. Most reviews assessed outcomes over a median follow-up of six weeks using standardized depression rating scales. Conclusions: Fluvoxamine is a robust and effective antidepressant, demonstrating consistent efficacy comparable to other antidepressants and superior to placebo. While no single antidepressant was universally superior, fluvoxamine’s unique pharmacological profile and favourable safety characteristics support its clinical utility. Further research is needed to explore its role in personalized treatment strategies and emerging therapeutic contexts, such as comorbid anxiety and post-traumatic stress disorder.

1 January 2024 in IEEE Canadian Journal of Electrical and Computer Engineering
Verified
Journal Article
Open access
ANAlaor Cervati Neto
Alaor Cervati Neto
ALAlexandre Levada
Alexandre Levada
MHMichel Haddad
Michel Haddad

28 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMichel Haddad
Michel Haddad
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
TVThiago Viola
Thiago Viola
MAMelissa Ribeiro de Araújo
Melissa Ribeiro de Araújo
Naielly Rodrigues da SilvaNaielly Rodrigues da Silva
Naielly Rodrigues da Silva
JMJair Mari
Jair Mari
Objective: This systematic review aims to evaluate the efficacy of fluvoxamine in the treatment of anxiety disorders and obsessive-compulsive disorder (OCD) by synthesizing evidence from systematic reviews and meta-analyses. Methods: We conducted a literature search in PubMed and the Cochrane Central Register of Controlled Trials, focusing on fluvoxamine’s efficacy in generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), and OCD. We included systematic reviews and meta-analyses of randomized controlled trials (RCTs) comparing fluvoxamine to a placebo or other drugs. The quality of evidence from the included reviews was assessed using A Measurement Tool to Assess Systematic Reviews—version 2 (AMSTAR-2). Results: The study included fourteen systematic reviews (five for OCD, three for SAD, and six for PD), covering thirty-seven RCTs (sixteen for OCD, six for SAD, and fifteen for PD), with a total of 3621 patients (1745 with OCD, 1034 with SAD, and 842 with PD). A high-quality systematic review demonstrated that fluvoxamine is superior to a placebo in improving symptoms and the response rates for OCD. Three meta-analyses comparing fluvoxamine to clomipramine in OCD found no significant differences in efficacy regarding symptom improvement. Two additional systematic reviews, both rated as high quality, confirmed the superiority of fluvoxamine in reducing symptom severity and improving the response rates in patients with SAD compared to a placebo. However, the findings for PD were inconsistent. A meta-analysis, also rated as high quality, found that while fluvoxamine showed better response rates than a placebo, the difference was not statistically significant. Conclusions: Overall, the efficacy of fluvoxamine in the treatment of OCD and SAD was demonstrated. While some reviews highlighted its potential in alleviating GAD, its impact on panic-specific outcomes remained inconsistent.

1 January 2019 in MethodsX
Verified
Journal Article
Open access
MHMichel Haddad
Michel Haddad
Aiming at supporting the process of investment portfolio diversification by using a data-driven approach, the present methodological paper proposes a new cluster analysis, which compares publicly traded companies, mainly in times of high volatility (e.g. crisis times). The main goal of the proposed method is to provide a less arbitrary analysis to support financial investors to precisely measure the degree of similarity between equity stocks, unveiling equity market clustering patterns by applying analytic geometry solutions and calculating an overall clustering pattern indicator. Empirical results on synthetic data demonstrate either that the proposed method has conceptual superiority over traditional cluster analyses and its potential practical usefulness to asset allocation, portfolio strategy, asset pricing, among other related purposes. Finally, the outputs of the proposed cluster analysis are presented through an intuitive and easily understandable mathematical visualization. •It is proposed a new method to calculate risk-similarity and clustering patterns.•The method unveils clustering patterns through a data-driven process.•Portfolio diversification can benefit from sphere-sphere intersection calculations.